The effect of simvastatin on asymmetric dimethylarginine and flow-mediated vasodilation after optimizing the LDL level - A randomized, placebo-controlled study

Vascular Pharmacology

Volumn 56, Issue 3-4, 2012, Pages 122-130

  Vladimirova Kitova, Lyudmila G ^a   Deneva Koycheva, Tanya I ^a  

^a MEDICAL UNIVERSITY OF PLOVDIV   (Bulgaria)

Author keywords

Asymmetric dimethylarginine; Flow mediated vasodilatation; Hypercholesterolemia; LDL cholesterol target; Simvastatin

Indexed keywords

APOLIPOPROTEIN B; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; N(G),N(G) DIMETHYLARGININE; PLACEBO; SIMVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FLOW RATE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

ADULT; APOLIPOPROTEINS B; ARGININE; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SIMVASTATIN; VASODILATION;

EID: 84858155583     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2011.10.004     Document Type: Article

References (63)

1. Ardigo D., Stuehlinger M., Franzini L., Valtueña S., Piatti P.M., Pachinger O., et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur. J. Clin. Invest. 2007, 37:263-269.
2. Beckman J.A., Liao J.K., Hurley S., Garret L.A., Chui D., Mitra D., Creager M.A. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low density lipoprotein. Circ. Res. 2004, 95:217-223.
3. Böger R.H. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin. Chem. Lab. Med. 2003, 41:1467-1472.
4. Böger R.H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann. Med. 2006, 38:126-136.
5. Böger R.H., Bode-Böger S.M., Brandes R.P., Phivthong-ngam L., Bohme M., Nafe R., Mugge A., et al. Dietary l-Arginine reduced the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997, 96:1282-1290.
6. Böger R.H., Bode-Böger S.M., Szuba A., et al. Asymmetric dimethylagrinine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998, 98:1842-1847.
7. Böger R.H., Bode-Böger S.M., Sydow K., Heistad D.D., Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocysteinemia or hypercholesterolemia. Atheroscler. Thromb. Vasc. Biol. 2000, 20:1557-1564.
8. Böger R.H., Sydow K., Borlak J., et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells. Circ. Res. 2000, 87:99-105.
9. Böger G.I., Maas R., Schwedhelm E., Bierend A., Benndorf R., Kastner M., Steenpaß A., Böger R.H. Improvement of endothelium-dependent vasodilation by simvastatin is potentiated by combination with l-arginine in patients with elevated asymmetric dimethylarginine levels. J. Am. Coll. Cardiol. 2004, 43(Suppl):525A.
10. Böger R.H., Cooke J.P., Vallance P. ADMA: an emerging cardiovascular risk factor. Vasc. Med. 2005, 10(Suppl 1):S1-S2.
11. Böger G.I., Rudolf T.K., Maas R., Schwedhelm E., Dumbadze E., Bieren A., Benudorf R.A., Böger R.H. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilatation by Simvastatin. Effect of combination with oral l-arginine. J. Am. Coll. Cardiol. 2007, 49:2274-2282.
12. Bolayirli I.M., Aslan M., Balci H., Altug T., Hacibekiroglu M., Seven A. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci. 2007, 81:121-127.
13. Celermajer D.S., Sorensen K.E., Gooch V.M., Spiegelhalter D.J., Miller O.I., Sullivan I.D., et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340:1111-1115.
14. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery: report of the international brachial artery reactivity task force. J. Am. Coll. Cardiol. 2002, 39:257-265.
15. Davignon J. The cardioprotective effects of statins. Curr. Atheroscler. Rep. 2004, 6:27-35.
16. Dupuis J., Tardif J.C., Cernacek P., Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999, 99:3227-3233.
17. Economodes P.A., Casselli A., Tiani E., Khaodhiar L., Horton E.S., Veves A. The effects of atorvastatin on endothelial function in diabetes patients and subjects at risk for type 2 diabetes. J. Clin. Endocrinol. Metab. 2004, 89:740-747.
18. Eid H.M., Eritsland J., Larsen J., Arnesen H., Seljeflot I. Increased levels of asymmetric dimethylarginine in population at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003, 166:279-284.
19. Favre A., Monpere C., Voyer C., Mirguet C., Quilliet-Thebaud N., Vernochet P., et al. How to improve primary prevention in asymptomatic high risk subjects. Eur. Heart J. 2004, 6(Suppl J):J59-J63.
20. Ganev, V.S., 2003. Mollecular genetic heterogeneity of the predisposition to atherosclerosis in Bulgaria. Medical University, Sofia, Bulgaria, 68-70 (Thesis).
21. Gornic H.L., Creager M.A. Arginine and endothelial and vascular health. J. Nutr. 2004, 134:2880S-2887S.
22. Greenland P., Abrams J., Aurigemma G.P., Bond G., Clark L.T., Criqui M.H., et al. Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000, 101:e16-e22.
23. Horvarth, A.D. 2001. Mollecular heterogeneity of LDLR and Apo B genes in healthy people and in patients with hypercholesterolemia in Bulgaria. Medical University, Sofia, Bulgaria, 68-69 (Thesis).
24. Horvath A., Chorbov V., Zaharova B., Ganev V. Five polymorphisms of the apolipoprotein B gene in healthy Bulgarians. Hum. Biol. 2003, 75(1):69-80.
25. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., Cooke J.P. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999, 99:3092-3095.
26. Ivashchenko C.Y., Bradley B.T., Ao Z., Leiper J., Vallance P., Douglas J.G. Regulation of the ADMA-DDAH system in endothelial cells: a novel mechanism for the response element dinding proteins, SREBP1c and -2. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H251-H258.
27. Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am. J. Cardiol. 2006, 97(8A):44C-51C.
28. Janatuinen T., Laakso J., Laaksonen R., Nuutila P., Lehtimaki T., Raitakari O.T., Knuuti J. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc. Med. 2003, 8:185-189.
29. Jang J.J., Ho H.K., Kwan H.H., Fajardo L.F., Cooke J.P. Angiogenesis is impaired by hypercholesterolemia: role of asymmetric dimethylarginine. Circulation 2000, 102:1414-1419.
30. Jiang J., Jiang D., Tang Y., Li N., Deng H., Li Y. Effect of simvastatin on endothelium dependent vasorelaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol. Sin. 2004, 25:893-901.
31. Jongh S., Lilien M.R., Roods J., Stroes E., Bakker H.D., Kastelein J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 2002, 40:2117-2121.
32. Jörvisalo M.J., Toikka J.O., Vasankari T., Mikkola J., Viikari J., Hartiala J., Raitakari O. HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. Atherosclerosis 1999, 147:237-242.
33. Juonala M., Viikari J., Alfthan G., Marniemi J., Kahonen M., Taittonen L., Laitinen T., Raitakari O.T. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007, 116:1367-1373.
34. Kielstein J.T., Donnerstag F., Gasper S., Menne J., Kielstein A., Martens-Lobenhoffer J., et al. ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke 2006, 37:2024-2029.
35. Laufs U., La F., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
36. Law M., Rudnicka A.R. Statin safety: a systematic review. Am. J. Cardiol. 2006, 97(8A):52C-60C.
37. Lu T.M., Ding Y.A., Leu H.B. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am. J. Cardiol. 2004, 94:157-161.
38. Martens-Lobenhoffer J., Westphal S., Awiszus F., Bode- Böger S.M., Luley C. Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA?. Clin. Chem. 2005, 51(11):2188-2189.
39. Miyazaki H., Matsuoka H., Cooke J., Usui M., Ueda S., Okuda S., Imaizuma T. Endogenous nitric oxide synthase inhibitor. Circulation 1999, 99:1141-1146.
40. Mullen M.J., Wright D., Donald A.E., Thorne S., Thomson H., Deanfield J.E. Atorvastatin but not l-Arginine improves endothelial function in type I diabetes mellitus: a doubleblind study. J. Am. Coll. Cardiol. 2000, 36:410-416.
41. Ogus A., Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with methabolic syndrome. Int. Heart J. 2008, 49:303-311.
42. Päivä H., Laakso J., Lehtimäki T., Isomustajärvi M., Ruoko I., Laaksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J. Cardiovasc. Pharmacol. 2003, 41:219-222.
43. Periera E.C., Bertolami M.C., Faludi A.A., Salem M., Bersch D., Abdalla D. Effects of simvastatin and L-arginine on vasodilation, nitric oxide metabolites and endogenous NOS inhibitors in hypercholesterolemic subjects. Free. Radic. Res. 2003, 37:529-536.
44. Santili F., Bucciarelli L., Noto D., Cefalù A.B., Davì V., Ferrante E., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 2007, 43:1255-1262.
45. Sasaki S., Kuwahara N., Kunitomo K., Harada S., Yamada T., Azuma A., et al. Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution and remnants lipoprotein in patients with mixed hyperlipoproteinemia. Am. J. Cardiol. 2002, 89:386-389.
46. Schuster H. Under-treated high risk patients: identifying patients in high-risk subgroup and treating them to LDL targets. Eur. Heart J. 2005, 7(Suppl A):20-28.
47. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999, 142:105-112. Scientific Steering Committee on behalf of the Simon Broome Register Group.
48. Sheu W.H., Juang B.L., Chen Y.T., Lee W.J. Endothelial dysfunction is not reversed by simvastatin treatment in type 2 diabetes patients with hypercholesterolemia. Diabetes Care 1999, 22:1224-1225.
49. Simons L.A., Sullivan D., Simons J., Celermajer D.S. Effects of atorvastatin monotherapy and simvastatin plus cholesteramine on arterial endothelial function in patients with severe primary hypercholesterolemia. Atherosclerosis 1998, 137:197-203.
50. Stühlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., Reaven G.M., Tsao P.S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420-1426.
51. Tsikas D., Böger R.H., Sandmann J., Bode-Böger S.M., Flolich J.C. Endogenous nitric oxide synthase inhibitors are responsible for the l-arginine paradox. FEBS Lett. 2000, 478:1-3.
52. Valkonen V.P., Laakso J., Päivä H., Lehtimaki T., Lakka T.A., Isomustajärvi M., et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?. Atherosclerosis 2003, 4(Suppl 4):19-22.
53. Valtonen P., Karppi J., Nyyssönen K., Valkonen V.P., Halonen K., Punnonen T. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J. Chromatogr. B 2005, 825(1-2):97-102.
54. Van Haelst P.L., Van Doormaal J.J., Asselbergs F.W., Van Roon A.M., Veeger N.J., Henneman M.M., et al. Correlates of endothelial function and their relationship with inflammation in patients with familial hypercholesterolemia. Clin. Sci. 2003, 104:627-632.
55. Van Venrooij F.V., Van de Ree M.A., Bots M.L., Stolk R.P., Huisman M.V., Banga J.D. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes. Diabetes Care 2002, 25:1211-1216.
56. Vladimirova-Kitova L., Deneva T.I., Angelova E., Bichev A.N., Nikolov F.P. Role of some biomarkers of atherogenic risk in the screening for molecular defects in the low density lipoprotein receptor in severe hypercholesterolemia. Folia Med. 2008, 50(3):14-22.
57. Vladimirova-Kitova L., Deneva T., Angelova E., Nikolov F., Marinov B., Mateva N. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clin. Physiol. Funct. Imaging 2008, 28:417-425.
58. Vladimirova-Kitova L., Deneva T., Marinov B. Effect of moderate and high-dose simvastatin on asymmetric dimethylarginine homocysteine metabolic pathways in patients with newly detected severe hypercholesterolemia. Cardiovasc. Ther 2010, 10.1111/j.1755-5922.2010.00149.
59. Vladimirova-Kitova L., Terzieva D., Nikolov F. Asymmetric dimethylarginine determines the effect of simvastatin on endothelium-dependent vasodilation in severe hypercholesterolemia. Clin. Lipidol. 2010, 5(1):29-41.
60. Vogel R.A., Correti M.C., Plotnick G.D. Changes in flow-mediated brachial artery vasoactivity with lowering of desirable cholesterol levels in healthy middle-aged men. Am. J. Cardiol. 1996, 77:37-40.
61. Wang J., Sim A.S., Wang X.L., Salonikas C., Naidoo D., Wilcken D.E.L. Relation between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary artery disease. Atherosclerosis 2006, 184:383-388.
62. Wolfrum S., Liao J. The pleiotropic effects of statins: relevance to their salutary effects. Statins: Understanding Clinical Use 2004, 163-187. J.L. Mehta, Saunders (Eds.).
63. Yu X.J., Li Y.J., Xiong Y. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci. 1994, 54:753-758.